Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Sep 25, 2026
Niagen Bioscience, Inc. (NAGE)
A forensic read on Niagen Bioscience, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
C · Mixed — selective
Forensic grade
Safe
Financial health
9.5
Distress distance
Clean
Earnings quality
3
Forensic signals
22.7%
ROE
$251M
Market cap
29.9%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence, going concern, valuation). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Niagen Bioscience, Inc. earns a C (Mixed — selective) forensic quality grade, and its balance-sheet distress test reads 9.5, placing it in the Safe zone. 3 forensic signals were flagged in its latest SEC filings, led by accruals ratio (% of noa).
What the filings flag
+191.8%
FY2024→FY2025
Accruals ratio (% of NOA).Net operating assets grew +191.8% relative to their own average in FY2025 — scaled by NOA itself, not by total assets, which is what the Forensic Screens card's own accrual row divides by. Accruals are building sharply — a large slice of profit sits in operating assets, not cash. An accrual is a claim that still has to be collected or written down, so the gap resolves in a later period whichever way it goes. The build is led by receivables up +25% against revenue +30%. A cash-flow measure on the same base agrees: reported earnings ran ahead of operating cash by 10% of net operating assets, against an accruals ratio of 191.8%. The two are computed differently: the accruals ratio is the change in net operating assets over average net operating assets, while the cash-flow figure is net income less operating cash flow over that same average.
+6.7%/yr
FY2023–FY2025
Share-count dilution.Diluted share count changed +14% over the last 2 years to FY2025 (+6.7%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~6.7% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2023 has been diluted ~12%.
5% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 5% of revenue in FY2025 — about $0.07 per diluted share. No cash left the business to pay it, which is why operating cash flow adds it back. Net of repurchases the diluted count still rose about 6.8% a year and that rate is not falling, so total profit has to grow by that much annually before any of it reaches a share. Stock compensation is one source of that issuance; acquisition consideration, equity raises, convertibles and other employee plans also net into the count, and these figures do not separate them.
Key fundamentals
Latest Revenue$129.4M
Revenue Growth YoY+29.9%
Revenue CAGR (2yr)+24.4%
Net Margin13.4%
Return on Equity22.7%
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Niagen Bioscience, Inc.'s actual 10-K/10-Q/8-K filings?